Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Bukwang Pharmaceutical (003000 KS)
Watchlist
39
Analysis
Health Care
•
South Korea
Bukwang Pharmaceutical Co., Ltd. produces oral hygienic, and pharmaceutical products. The Company's products include over-the-counter drugs, toothpastes, and toothbrushes.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
07 Jul 2016 00:13
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
Sanghyun Park
Follow
3.6k Views
Share
bearish
•
Quantitative Analysis
•
29 Jul 2025 17:55
KRX Short Interest Weekly (Jul 25th): LG Chem, Shinhan Group, Hanwha Ocean, Samsung Electronics, SCD
We analyzed KRX short interest report for the past week and highlighted short interest changes in LG Chem, Shinhan Group, Hanwha Ocean, Samsung...
Ke Yan, CFA, FRM
Follow
447 Views
Share
bearish
•
Quantitative Analysis
•
23 Jul 2025 07:05
KRX Short Interest Weekly (Jul 18th): Kakaopay, Korzinc, SK Hynix, Samsung Sds, Hanwha Aerospace
We analyzed KRX short interest report for the past week and highlighted short interest changes in Kakaopay, Korzinc, SK Hynix, Samsung Sds, Hanwha...
Ke Yan, CFA, FRM
Follow
464 Views
Share
bearish
•
Quantitative Analysis
•
09 Jul 2025 10:20
KRX Short Interest Weekly (Jul 4th): Hanwha Ocean, Hyundai Rotem, Kiwoom, Doosan Enerbility, Cosmax
We analyzed KRX short interest report for the past week and highlighted short interest changes in Hanwha Ocean, Hyundai Rotem, Kiwoom, Doosan...
Ke Yan, CFA, FRM
Follow
469 Views
Share
bearish
•
Bukwang Pharmaceutical
•
28 Mar 2025 19:02
Bukwang Pharm Announces A Capital Raise of 100 Billion Won
On 28 March, Bukwang Pharmaceutical announced a capital raise of 100 billion won. The company plans to issue 30.2 million new shares (44% of...
Douglas Kim
Follow
454 Views
Share
Previous
1
2
3
4
5
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x